Seladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Open Access
- 28 February 2026
- journal article
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 1 (42) , 87-94
Abstract
Primary biliary cholangitis (PBC) is an autoimmune disease that is characterized by the continuous destruction of small bile ducts within the liver, primarily affecting women aged 40-65. The condition leads to cholestasis and potential liver failure, necessitating effective treatment strategies. Seladelpar (MBX-8025) is a novel selective peroxisome proliferator-activated receptor (PPAR)-delta agonist that has been pioneered to address the unmet need in PBC management. Recent trials demonstrate that seladelpar significantly reduces alkaline phosphatase (ALP) levels and improves patients overall biochemical response, particularly in those intolerant or nonresponsive to UDCA. Particularly, seladelpar regulates bile acid metabolism via suppression of CYP7A1 and elevation of FGF21, contributing to its anti-inflammatory and antifibrotic actions. As a promising experimental drug, seladelpar could reshape treatment approach for PBC, providing an alternative treatment for patients who do not respond adequately to existing therapies due to inadequate responses.Keywords
This publication has 21 references indexed in Scilit:
- Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathwayJournal of Biological Chemistry, 2022
- A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisJournal of Hepatology, 2022
- FXR in liver physiology: Multiple faces to regulate liver metabolismBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- Primary biliary cholangitisThe Lancet, 2020
- New treatments/targets for primary biliary cholangitisJHEP Reports, 2019
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver DiseasesHepatology, 2018
- Seladelpar’s mechanism of action as a potential treatment for primary biliary cholangitis and non-alcoholic steato-hepatitisJournal of Hepatology, 2018
- Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyThe Lancet Gastroenterology & Hepatology, 2017
- The ascending pathophysiology of cholestatic liver diseaseHepatology, 2016
- The immunogenetics of primary biliary cirrhosis: A comprehensive reviewJournal of Autoimmunity, 2015